NHS England updates CDF List
NHS England updates CDF List
NHS England has updated the Cancer Drugs Fund List. The latest version (v1.371) was uploaded to the NHS England Website on Wednesday 6, August 2025.
The following changes have been introduced:
Pembrolizumab in combination with platinum-containing chemotherapy (carboplatin and paclitaxel) (PEMB32)
Pembrolizumab in combination with platinum-containing chemotherapy (carboplatin and paclitaxel) for the 1st line treatment of mismatch repair deficient (dMMR) or microsatellite instability-high endometrial carcinoma in adult patients who have recurrent or primary advanced disease and who are not candidates for potentially curative surgery or radiotherapy or chemoradiotherapy but are eligible for systemic therapy where the following criteria have been met
Recommended for routine commissioning, receiving CDF interim funding
NA (BRE15)
NA
Moved into routine commissioning - section B of list
NA (OSI4)
NA
Moved into routine commissioning - section B of list